# Cellibre

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellibre

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.cellibre.com
- Total disclosed funding: $12M
- Latest round: Series A (Oct 13, 2021)
- Investors on record: 5

## About

Cellibre, Inc. is a biotechnology company focused on producing sustainable products through advanced biological processes, including precision fermentation and strain engineering, to address environmental challenges.Founded in 2017, Cellibre, Inc. is headquartered in San Diego, US. The company specializes in biochemistry and is known for its innovative approach to sustainable production methods. The founding team includes Ben Chiarelli, Nicky Caiazza, Robert Baurys, Scott Zingheim, and Spiros Kambourakis, with Ben Chiarelli serving as CEO. Cellibre has successfully completed 3 funding deals, with the latest being a Series A round in October 2021, raising USD 11.5 mn led by Merida Capital Holdings, alongside investments from Delta Emerald Ventures, Entourage Effect Capital, Flatiron Venture Partners, and Liquid 2 Ventures, totaling USD 11.5 mn raised to date.Cellibre specializes in utilizing advanced biological processes to produce sustainable products through innovative manufacturing technologies. Their core offerings include strain engineering, precision fermentation, and biochemistry, which together enable the creation of high-value products to address environmental challenges. By harnessing nature's machinery, Cellibre transforms biological processes into efficient production methods, moving away from traditional agricultural practices to fermentation-based manufacturing. This approach allows the company to produce a diverse range of products with minimal resources while maintaining high quality, serving clients across North America and Europe in various sustainability-focused industries.Cellibre's revenue model is structured around strategic partnerships and direct business-to-business transactions, collaborating with organizations focused on sustainable practices. Their clients span the food, health, and industrial sectors, utilizing Cellibre’s innovative products to enhance their offerings. Transactions may involve direct sales agreements or joint ventures that facilitate the implementation of Cellibre's technologies in clients’ production processes. The value of their flagship products, derived from precision fermentation and strain engineering, is emphasized, leading to mutually beneficial financial arrangements with partners, with pricing plans tailored to client needs reflecting the bespoke nature of their offerings.In October 2021, Cellibre, Inc. raised USD 11.5 mn in Series A funding, led by Merida Capital Holdings, to expand its operations and commercialize its cultured cannabinoid platform. The funding will support the development of upcoming new products and enhance their capabilities in production processes. The company aims to expand into new markets, specifically targeting additional regions in North America and Europe by 2023.

## Funding rounds

- Series A, Oct 13, 2021, $12M — Liquid 2 Ventures, Merida Capital Holdings, Entourage Effect Capital, Flatiron Venture Partners, Delta Emerald Ventures

## Investors

- Liquid 2 Ventures (https://capitalatlas.ai/funds/liquid-2-ventures) — Series A
- Merida Capital Holdings (https://capitalatlas.ai/funds/merida-capital-holdings) — Series A
- Entourage Effect Capital (https://capitalatlas.ai/funds/entourage-effect-capital) — Series A
- Flatiron Venture Partners (https://capitalatlas.ai/funds/flatiron-venture-partners) — Series A
- Delta Emerald Ventures (https://capitalatlas.ai/funds/delta-emerald-ventures) — Series A